Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Change in Accured Expenses: 2016-2025

Historic Change in Accured Expenses for Tg Therapeutics (TGTX) over the last 10 years, with Sep 2025 value amounting to -$17.3 million.

  • Tg Therapeutics' Change in Accured Expenses fell 248.08% to -$17.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.9 million, marking a year-over-year decrease of 75.94%. This contributed to the annual value of $22.8 million for FY2024, which is 753.76% up from last year.
  • Tg Therapeutics' Change in Accured Expenses amounted to -$17.3 million in Q3 2025, which was down 410.51% from $5.6 million recorded in Q2 2025.
  • In the past 5 years, Tg Therapeutics' Change in Accured Expenses ranged from a high of $65.6 million in Q1 2025 and a low of -$38.0 million during Q4 2024.
  • In the last 3 years, Tg Therapeutics' Change in Accured Expenses had a median value of $9.0 million in 2024 and averaged $7.2 million.
  • As far as peak fluctuations go, Tg Therapeutics' Change in Accured Expenses skyrocketed by 501.74% in 2021, and later plummeted by 7,560.96% in 2022.
  • Tg Therapeutics' Change in Accured Expenses (Quarterly) stood at -$28.2 million in 2021, then spiked by 158.17% to $16.4 million in 2022, then crashed by 69.27% to $5.0 million in 2023, then slumped by 853.16% to -$38.0 million in 2024, then crashed by 248.08% to -$17.3 million in 2025.
  • Its Change in Accured Expenses stands at -$17.3 million for Q3 2025, versus $5.6 million for Q2 2025 and $65.6 million for Q1 2025.